Search

everythinglearnresearchcommunity

for

Search:↓

Most patients with Central Centrifugal Cicatricial Alopecia at the reviewed institution were middle-aged Black women, often with no symptoms, and commonly treated with topical medications.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Certain mouse strains develop a skin condition similar to a human hair loss disease due to genetic defects.

Hair breakage may be an early sign of a hair loss condition called CCCA in African American women.

Genes linked to fibrosis are more active in people with central centrifugal cicatricial alopecia.

The study found that Central Centrifugal Cicatricial Alopecia mainly affects middle-aged African descent women, is linked to certain hair care practices and genetics, and often goes undiagnosed for years.

The conclusion is that hair loss from CCCA may be genetic and not solely caused by hair grooming practices.

Severe CCCA may be biologically and clinically different from milder forms.

Patients with central centrifugal cicatricial alopecia may have a higher risk of breast and colorectal cancer.

Dermatoscopy can help diagnose CCCA without visible hair loss, offering a less invasive option than biopsy.

PRP therapy can temporarily grow hair in CCCA patients but isn't a permanent cure.

CCCA involves immune response and metabolism issues, suggesting new treatment options.

CCCA may be a fibroproliferative disorder, and anti-fibrotic therapies could help.

Topical metformin may improve hair regrowth in CCCA when added to standard treatments.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

A new plant-based treatment was effective for hair regrowth in women with a specific type of hair loss that didn't respond to usual treatments.

CCCA causes progressive hair loss in Black women, starting from a central scalp patch.

Genetic variants in specific genes cause central centrifugal cicatricial alopecia.

Genetic variants in specific genes cause a type of hair loss.

There is no standard treatment for CCCA, and practices vary widely.

The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.

CCCA and LPP may be related hair loss conditions influenced by genetics and environment, needing early treatment.

Low-dose metformin may help hair regrowth and reduce inflammation in CCCA.

Topical metformin 10% cream may help treat central centrifugal cicatricial alopecia.

Allergens might contribute to CCCA, so avoiding them could help manage the condition.

CCCA is a scarring hair disorder mainly affecting people of African descent, needing better awareness and treatment.

Patients with central centrifugal cicatricial alopecia often have higher rates of metabolic, autoimmune, and atopic conditions, as well as anxiety and depression.

Certain hairstyles, diabetes, scalp infections, and vitamin D deficiency may increase the risk of hair loss in Black women; more research is needed for better treatment.

CCCA and lichen planopilaris have similar histological features, making them hard to distinguish.